Computational Bioscience Laboratory, Department of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä , P.O. Box 35, Jyväskylä FI-40014, Finland.
J Chem Inf Model. 2013 Oct 28;53(10):2626-33. doi: 10.1021/ci4002475. Epub 2013 Sep 13.
Filamins (FLN) are large dimeric proteins that cross-link actin and work as important scaffolds in human cells. FLNs consist of an N-terminal actin-binding domain followed by 24 immunoglobulin-like domains (FLN1-24). FLN domains are divided into four subgroups based on their amino acid sequences. One of these subgroups, including domains 4, 9, 12, 17, 19, 21, and 23, shares a similar ligand-binding site between the β strands C and D. Several proteins, such as integrins β2 and β7, glycoprotein Ibα (GPIbα), and migfilin, have been shown to bind to this site. Here, we computationally estimated the binding free energies of filamin A (FLNa) subunits with bound peptides using the molecular mechanics-generalized Born surface area (MMGBSA) method. The obtained computational results correlated well with the experimental data, and they ranked efficiently both the binding of one ligand to all used FLNa-domains and the binding of all used ligands to FLNa21. Furthermore, the steered molecular dynamics (SMD) simulations pinpointed the binding hot spots for these complexes. These results demonstrate that molecular dynamics combined with free energy calculations are applicable to estimating the energetics of protein-protein interactions and can be used to direct the development of novel FLN function modulators.
细丝蛋白(Filamin,FLN)是一种大型二聚体蛋白,能够交联肌动蛋白并在人体细胞中充当重要的支架。FLN 由一个 N 端肌动蛋白结合结构域和 24 个免疫球蛋白样结构域(FLN1-24)组成。FLN 结构域根据其氨基酸序列分为四个亚组。其中一个亚组,包括结构域 4、9、12、17、19、21 和 23,在 β 链 C 和 D 之间共享一个类似的配体结合位点。已经证明,几种蛋白质,如整合素 β2 和 β7、糖蛋白 Ibα(GPIbα)和迁移蛋白(migfilin),能够与该位点结合。在这里,我们使用分子力学-广义 Born 表面积(MMGBSA)方法计算了结合肽的细丝蛋白 A(FLNa)亚基的结合自由能。所得到的计算结果与实验数据很好地相关,并且它们有效地对一个配体与所有使用的 FLNa 结构域的结合以及所有使用的配体与 FLNa21 的结合进行了排序。此外,导向分子动力学(SMD)模拟确定了这些复合物的结合热点。这些结果表明,分子动力学与自由能计算相结合可用于估计蛋白质-蛋白质相互作用的能量学,并且可用于指导新型 FLN 功能调节剂的开发。